FY22 Invention Disclosures
FY22 U.S. Patents Issued
FY22 Licensing Revenue
FY22 New IP Based Startups
This is WashU Innovation
The Office of Technology Management assists WashU faculty in the transfer of technology from the lab to the global marketplace.
Explore our innovation community
A research powerhouse becomes an innovation incubator
“We believe in the idea that research can improve health outcomes, decrease health-care costs and improve the regional economy.” — David H. Perlmutter, MD, executive vice chancellor for medical affairs and the George and Carol Bauer Dean of the School of Medicine
St. Louis-based clinical-stage biotechnology startup Wugen, which has raised more than $200 million in venture funding, has launched a clinical trial for one of its cancer-fighting therapies.
Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that the first patient has been dosed in a Phase 1/2 trial of WU-CART-007 for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).
Randall Bateman, M.D. — the Charles F. and Joanne Knight Distinguished Professor of Neurology — and colleagues set out to determine the diagnostic accuracy of a new blood test for detecting early signs of AD.
Resources for Students & Alumni
The Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship serves as the primary resource for students and alumni.